Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

Lennard, Colleen M.; Patel, Aneeta; Wilson, J D; Reinhardt, Brian; Tuman, Caroline; Fenton, Cydney; Blair, Elizabeth A.; Francis, Gary L.; Tuttle, R. Michael

doi:10.1067/msy.2001.112592

Cited by 142 publications

(76 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As already shown in other tumor types, recent studies in thyroid cancer have demonstrated the prognostic significance of necrosis and proliferation, estimated by the number of mitoses (Akslen & LiVolsi 2000, Hiltzik et al 2006. Furthermore, immunohistochemistry may detect the expression of proteins involved in iodine metabolism (sodium iodine symporter (NIS), thyroglobulin (Tg), thyroid peroxidase (TPO), apical iodine transporter (AIT), and dual-oxidase (p138-DUOX)), FDG uptake (glucose transporter 1 (GLUT-1) and hexokinase; Dupuy et al 2000, De Deken et al 2002, Schönberger et al 2002, Lacroix et al 2004, and angiogenesis, such as vascular endothelial growth factor (VEGF) and VEGF receptor (VEGF-R) (Bunone et al 1999, Katoh et al 1999, Klein et al 2001, Lennard et al 2001). These three features were shown to be related to thyroid cancer prognosis.…”

Section: Introductionmentioning

confidence: 99%

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Deandreis¹,

Ghuzlan²,

Leboulleux³

et al. 2010

Endocrine Related Cancer

160

View full text Add to dashboard Cite

The aim of this study is to search for relationships between histology, radioiodine ( 131 I) uptake, fluorodeoxyglucose (FDG) uptake, and disease outcome in patients with metastatic thyroid cancer. Eighty patients with metastatic thyroid cancer (34 males, 46 females, mean age at the time of the diagnosis of metastases: 55 years) were retrospectively studied. All patients were treated with radioactive iodine and evaluated by FDG-positron emission tomography (PET). Primary tumor tissue sample was available in all cases. Forty-five patients (56%) had a papillary, 12 (15%) a follicular, and 23 (29%) a poorly differentiated thyroid cancer. Cellular atypias, necrosis, mitoses, thyroid capsule infiltration, and vascular invasion were frequently detected (70, 44, 52, 60, and 71% respectively). Metastases disclosed FDG uptake in 58 patients (72%) and 131 I uptake in 37 patients (45%). FDG uptake was the only significant prognostic factor for survival (PZ0.02). The maximum standardized uptake value and the number of FDG avid lesions were also related to prognosis (PZ0.03 and 0.009). Age at the time of the diagnosis of metastases (PZ0.001) and the presence of necrosis (PZ0.002) were independent predictive factors of FDG uptake. Radioiodine uptake was prognostic for stable disease (PZ0.001) and necrosis for progressive disease at 1 year (PZ0.001). Histological subtype was not correlated with in vivo tumor metabolism and prognosis. In conclusion, FDG uptake in metastatic thyroid cancer is highly prognostic for survival. Histological subtype alone does not correlate with 131 I/FDG uptake pattern and patient outcome. Well-differentiated thyroid cancer presenting histological features such as necrosis and FDG uptake on PET scan should be considered aggressive differentiated cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Deandreis¹,

Ghuzlan²,

Leboulleux³

et al. 2010

Endocrine Related Cancer

160

View full text Add to dashboard Cite

show abstract

“…Despite a number of studies published on angiogenesis in diff erent tumor types, endocrine neoplasms have not been subjected to extensive investigation. There are few reports on tumor angiogenesis in the hypophysis 58 , in pheochromocytomas 59 , in thyroid papillary carcinoma 60,61 and medullary carcinoma 62 . Ryska et al examined microvessel density in the thyroid gland by using endothelial marker CD31.…”

Section: Discussionmentioning

confidence: 99%

Potential Diagnostic Markers in Nodular Lesions of the Thyroid Gland: An Immunohistochemical Study

Rydlová¹,

Ludvíková²,

Stankova³

2008

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims:The diff erential diagnosis of thyroid nodules in routine practice can be problemmatic for both pathologists and clinicians. Eff ective treatment requires a determination of the biological nature of the lesions. For this reason, ancilliary diagnostic markers along with histological examination of the nodules may be useful. The objective of this study was to evaluate the diagnostic usefulness of novel markers in the diagnosis of hyperplastic and neoplastic nodules.Methods: Forty eight thyroid lesions forming four diagnostic groups including adenomatous goiters (AS), follicular adenomas (FA), follicular (FC) and papillary carcinomas (PC) were examined using standard immunohistochemical methods. Monoclonal antibodies against galectin-3, matrix metalloproteinases (MMPs) -2 and -7 and endothelial markers CD31 and CD105 were used.Results: The cytoplasmatic expression of galectin-3 was positive in all cases of papillary carcinoma. Moreover, statistically signifi cant diff erences between fused groups of benign (AS and FA) and malignant lesions (FC and PC) were found Fischer's exact test (p = 0.0001). No signifi cant diff erences in cytoplasmic expression of MMPs -2 and -7 and in vascular density assessed by using of both endothelial markers between benign lesions and malignant tumors were revealed.Conclusions: Galectin-3 appears to be a useful marker in the diagnosis of papillary carcinoma only. The matrix metalloproteinases-2 and -7 are not helpful in distinguishing hyperplastic and neoplastic thyroid nodules. Endothelial markers do not appear to be suitable for thyroid diff erential diagnosis. A panel of antibodies in the diff erential diagnosis of thyroid nodular lesions would seem most suitable and further studies with larger sets of patients are awaited.

show abstract

“…Although it has been known for decades that angiogenesis is central to tumor development, we consider it relevant to mention its role in thyroid cancer pathogenesis (Lennard et al 2001, Lewy-Trenda & Wierzchniewska-Lawska 2002, Tanaka et al 2002, Bauer et al 2003, Lin et al 2003 due to recent availability of potent and specific inhibitors of angiogenesis in the clinic. In order for tumors to grow and metastasize, they must acquire angiogenic capability (Gullino 1978) to provide their own blood supply.…”

Section: Novel Insights In the Pathogenesis Of Thyroid Cancermentioning

confidence: 99%

New therapeutic advances in the management of progressive thyroid cancer

Woyach¹,

Shah²

2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified. Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC). While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary. Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone suppression and radioactive iodine therapy. However, for the iodinerefractory DTC, MTC, and ATC there is no effective systemic standard of care treatment. Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in thyroid cancer. Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types of thyroid cancers with some remarkable results that has made an impact on lives of patients with thyroid cancer. Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for thyroid cancer.

show abstract

Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer

Cited by 142 publications

References 24 publications

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

Potential Diagnostic Markers in Nodular Lesions of the Thyroid Gland: An Immunohistochemical Study

New therapeutic advances in the management of progressive thyroid cancer

Contact Info

Product

Resources

About